**Eternal CEO Addresses Criticism Over Health-Monitoring Device Temple**
Deepinder Goyal, the founder and CEO of Eternal, the parent company of Zomato, clarified on January 9 that no public announcements regarding the health-monitoring device known as Temple have been made yet, despite facing criticism from medical professionals and influencers. He emphasized that official benchmarking data for the device has not been released, and the launch of preview devices is still some months away.
In a post on the social media platform X, Goyal addressed concerned doctors and influencers, stating, “We haven’t made any public commercial announcements about Temple yet. We haven’t released any official device benchmarking data. A lot of the work is still underway; we’re months away from introducing preview devices to the public, if at all.”
His comments come in response to criticism from some medical experts regarding the wearable device, which Goyal was seen wearing during a recent appearance on Raj Shamani’s YouTube podcast. Some healthcare professionals have raised questions about the device’s legitimacy and accuracy.
Goyal found the situation amusing and criticized those advising against purchasing an unvalidated device that is not yet available for order. “You are advising people not to buy an ‘unvalidated’ device that isn’t even available to order or pre-order yet. That’s funny,” he remarked.
He assured the public that comprehensive scientific information would be shared if and when they decide to sell Temple, encouraging curiosity and support for Indian startups. “Your skepticism is valuable, but at the right time,” he added.
**What is Temple?**
The Temple is an experimental device designed to continuously monitor blood flow in the brain in real-time. Goyal was seen wearing this small sensor, which is available in gold or silver, during his podcast appearance. The device aims to track blood flow to the brain, a crucial indicator of neurological health and aging. It is based on Goyal’s personal research into the ‘Gravity Ageing Hypothesis,’ and he has invested $25 million of his own funds into its development.
**Criticism of Temple**
Dr. Cyriac Abbey Philips, known online as The Liver Doc, criticized Goyal for promoting what he described as an “ancient, already debunked gravitational theory of aging” to market a wellness product. He argued that the device lacks scientific backing and likened it to “a fat band-aid stuck to the temple,” cautioning against the spread of misinformation in the wellness industry.
In summary, while Goyal remains optimistic about the potential of Temple, the device continues to face scrutiny from the medical community, highlighting the importance of scientific validation in health technology.
**FAQ**
**What is the purpose of the Temple device?**
The Temple device is designed to continuously monitor blood flow in the brain, providing real-time data that may serve as an important marker for neurological health and aging.
